Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

(2021) L. S. Kaertner et al.   Scientific Reports

Self-blinding citizen science to explore psychedelic microdosing

(2021) Balázs Szigeti et al.   eLife

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

(2020) Nadia R.P.W. Hutten et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

(2019) Thomas Anderson et al.   PSYCHOPHARMACOLOGY

A systematic study of microdosing psychedelics

(2019) Vince Polito et al.   PLoS One

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

(2019) Martin K. Madsen et al.   NEUROPSYCHOPHARMACOLOGY

Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents

(2019) Lindsay P. Cameron et al.   ACS Chemical Neuroscience

Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers

(2019) Anya K. Bershad et al.   BIOLOGICAL PSYCHIATRY

Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers

(2019) Nadia R. P. W. Hutten et al.   Frontiers in Psychiatry

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

(2019) Neiloufar Family et al.   PSYCHOPHARMACOLOGY

Psilocin and ketamine microdosing

(2018) Rachel R. Horsley et al.   BEHAVIOURAL PHARMACOLOGY

Psychedelics Promote Structural and Functional Neural Plasticity

(2018) Calvin Ly et al.   Cell Reports

Antidepressants Accumulate in Lipid Rafts Independent of Monoamine Transporters to Modulate Redistribution of the G Protein, Gαs

(2016) Samuel J. Erb et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers

(2015) Rainer Kraehenmann et al.   BIOLOGICAL PSYCHIATRY

Whatever next? Predictive brains, situated agents, and the future of cognitive science

(2013)   BEHAVIORAL AND BRAIN SCIENCES

Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin

(2013) F. Bernasconi et al.   CEREBRAL CORTEX

Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors

(2012) Michael Kometer et al.   BIOLOGICAL PSYCHIATRY

The Multidimensional Assessment of Interoceptive Awareness (MAIA)

(2012) Wolf E. Mehling et al.   PLoS One

The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions

(2012) André Schmidt et al.   PSYCHOPHARMACOLOGY

On the embodiment of emotion regulation: interoceptive awareness facilitates reappraisal

(2012) Jürgen Füstös et al.   Social Cognitive and Affective Neuroscience

Depression, Antidepressants and Neurogenesis: A Critical Reappraisal

(2011) Nicola D Hanson et al.   NEUROPSYCHOPHARMACOLOGY

Introduction to placebo effects in medicine: mechanisms and clinical implications

(2011) K. Meissner et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Structural and synaptic plasticity in stress-related disorders

(2011) Daniel J. Christoffel et al.   REVIEWS IN THE NEUROSCIENCES

Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action

(2009) Catherine J. Harmer et al.   BRITISH JOURNAL OF PSYCHIATRY